Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790718 | 0.87 | GRIK1 (0.45) | GRIK1GRIK2CYP1A2MMEPPARG | |
| SCHEMBL6791072 | 0.86 | CYP1A2 (0.59) | CYP1A2MMECPA1 | |
| SCHEMBL6789903 | 0.85 | PPARA (0.51) | GRIK1GRIK2PPARGPPARA | |
| SCHEMBL7384829 | 0.79 | CYP1A2 (0.65) | CYP1A2MMEPPARGPPARACPA1 | |
| SCHEMBL6791884 | 0.77 | CPA1 (0.43) | GRIK1GRIK2CYP1A2MMEPPARG | |
| SCHEMBL5378074 | 0.76 | CYP1A2 (0.57) | CYP1A2PPARGPPARACPA1 | |
| SCHEMBL12493679 | 0.76 | CYP1A2 (0.55) | CYP1A2MMEPPARGPPARACPA1 | |
| SCHEMBL16798335 | 0.74 | MME (0.57) | CYP1A2MMEPPARGPPARATRPA1 | |
| SCHEMBL28181738 | 0.74 | CYP1A2 (0.77) | CYP1A2MMEPPARGPPARACPA1 | |
| SCHEMBL29865172 | 0.73 | PPARA (0.56) | CYP1A2PPARGPPARACPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-6995142-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1329457-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMA (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6906198-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PETER DRAGOVICH S (US) | 2004-04-15 | — | — | US | disclosed |
| US-6649639-B2 | Inhibit or block the biological activity of the picornaviral 3C protease. | DRAGOVICH PETER S (US) | 2003-11-18 | — | — | US | disclosed |
| EP-0975588-B1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-1329457-A2 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | DRAGOVICH PETER SCOTT (US) | 2003-07-10 | — | — | US | disclosed |
| US-6531452-B1 | Peptide-like and peptidomimetic compounds that inhibit enzymatic activity of picornaviral 3C proteases and inhibit picornavirus replication | AGOURON PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | DRAGOVICH PETER S (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331554-B1 | PICORNAVIRUS PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-1073672-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0975588-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6020371-A | VIRICIDES; PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999057135-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1998043950-A1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | RNASEL, RNASE1, GTF3C3 | GRIK1 3932/4885GRIK2 4225/4885CYP1A2 2658/4885 |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PCNA, ZC3HAV1, POLR1C | GRIK1 3525/4885GRIK2 4032/4885CYP1A2 4849/4885 |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | GRIK1 4191/4885GRIK2 4283/4885CYP1A2 2856/4885 |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | SARNP, RNASE1, SERPINA3 | GRIK1 3949/4885GRIK2 4226/4885CYP1A2 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.